Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL62 + Orelabrutinib in R/R CD20+ B-cell Lymphoma
NCT04304040Phase 2Active, not recruiting
- Sponsor
- InnoCare Pharma
- Start
- Jul 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab beta, orelabrutinib in B cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by InnoCare Pharma. Started Jul 2020; status: active, not recruiting.
02
Drugs
obinutuzumab betaorelabrutinib
03
Conditions
B cell lymphomachronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04304040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04304040.